Abstract Brain metastases commonly occur in patients with breast, lung and melanoma systemic cancers. The anti-a V integrin monoclonal antibody intetumumab binds cell surface proteins important for adhesion, invasion and angiogenesis in the metastatic cascade. The objective of this study was to investigate the anti-metastatic effect of intetumumab in a hematogenous breast cancer brain metastasis model. Female nude rats received intra-carotid infusion of human brain-seeking metastatic breast cancer cells (231BR-HER2) and were randomly assigned into four groups: (1) control; (2) intetumumab mixed with cells in vitro 5 min before infusion without further treatment; (3) intetumumab intravenously 4 h before and weekly after cell infusion; (4) intetumumab intravenously weekly starting 7 days after cell infusion. Brain metastases were detected by magnetic resonance imaging (MRI) and immunohistochemistry. Comparisons were made using the Kruskal-Wallis test and Dunnett's test. Survival times were estimated using Kaplan-Meier analysis. All control rats with brain tissue available for histology (9 of 11 rats) developed multiple brain metastases (median = 14). Intetumumab treatment either in vitro prior to cell infusion or intravenous before or after cell infusion prevented metastasis formation on MRI and decreased the number of metastases on histology (median = 2, p = 0.0055), including 30 % of animals without detectable tumors at the end of the study. The overall survival was improved by intetumumab compared to controls (median 77? vs. 52 days, p = 0.0277). Our results suggest that breast cancer patients at risk of metastases might benefit from early intetumumab treatment.
Introduction
Brain metastasis occurs in as many as one third of breast cancer patients, and is associated with high mortality [1] . Methods to prevent or delay formation of breast cancer brain metastases would have a significant health benefit. A HER2-overexpressing clone of a brain-seeking derivative of MDA-MB-231 human breast cancer cells (231BR-HER2 cells) consistently forms multiple brain hematogenous metastases and provides a model for testing anti-metastatic therapies [2] [3] [4] . The hematogenous metastatic breast cancer model used in this study mimics the clinical situation: successful metastasis of high HER2 breast cancer cells that travel through the bloodstream, adhere to the blood vessels in the brain, invade the brain parenchyma, and grow in the new environment [5] .
Integrins are a large family of heterodimeric integral membrane proteins comprising at least 24 combinations of 18 a and 8 b subunits. These receptors are involved in cellcell and cell-extracellular matrix (ECM) interactions, cytoskeleton organization, and cell signaling. In cancer, integrins promote the proliferation of tumor cells and tumor vascular endothelial cells [6] [7] [8] [9] , and appear to be involved in multiple aspects of metastasis, including tumor cell binding, invasion, growth and angiogenesis [9] [10] [11] [12] . The involvement of integrins in multiple steps of the metastatic process and their differential expression between tumors and normal tissue makes them a promising therapeutic target [13] [14] [15] [16] .
Intetumumab (INT; CNTO 95) is a fully human IgG1k monoclonal antibody (mAb) that binds a V integrins with broad specificity, with a dissociation constant of K d 1-24 nmol [17, 18] . It has a serum half life of 8-9 days and was found to be well tolerated with no or relatively low adverse effects at 10 mg/kg in clinical phase I and II trials [17, [19] [20] [21] . The objective of this study was to investigate the anti-metastatic effect of intetumumab in a hematogenous breast cancer brain metastasis model in nude rats.
Materials and methods
The care and use of the animals was approved by the Institutional Animal Care and Use Committee and was under the supervision of the Department of Comparative Medicine at OHSU. Intetumumab (fully human anti-a V integrin mAb) was provided by Ortho Biotech Oncology R&D (Radnor, PA). Other antibodies used were trastuzumab (anti-HER2) and rituximab (anti-CD20) (Genentech, San Francisco, CA), anti-human a V , a 5 , b 3 , b 5 integrin and HER2 (Cell Signaling Technology, Danvers, MA), anti-human mitochondrial antigen (Chemicon/Millipore Temecula, CA), and antitubulin (Sigma, St. Louis, MO). Cyclophosphamide (Cytoxan Ò ) was from Bristol-Myers Squibb (Princeton, NJ).
Cell culture and in vitro studies
Human metastatic breast cancer cells (MDA-MB-231BR-HER2; 231BR-HER2) and a matched plasmid-transfected cell line without HER2 protein overexpression (231BR-vector) were provided by Dr. Pat Steeg (NCI, Bethesda, MD) and were cultured with DME medium supplemented with serum and antibiotics. Cellular integrin protein expression in cultured cells was characterized using the Alpha/Beta Integrin-Mediated Cell Adhesion Assay Combo Kit (Chemicon/ Millipore, Temecula, CA) and immunobloting analysis. Western immunobloting was performed as described previously [22] . For the cell trafficking study, 231BR-HER2 cells were labeled in vitro with ferumoxides-protamine sulfate (FE-Pro) complex (100 lg/mL; w/w; 10:1 ratio) in serum free medium for 1 h, then rinsed in serum-free medium prior to intra-carotid infusion [23] . For the in vitro adhesion assay, 10 5 231BR-HER2 cells were treated with 0.5 mg/mL intetumumab, trastuzumab or rituximab antibody in complete medium. After 1 h incubation at 37°C, the unattached cells were gently pipetted and counted after trypan blue staining.
Study designs

Hematogenous breast cancer brain metastasis model
Female nude rats (rnu/rnu, 200-250 g, from the OHSU Blood-Brain Barrier Program in-house colony) were used for all studies. Rats were pretreated with cyclophosphamide (100 mg/kg IP) 1 day before cell infusion to reduce innate immunity and 14 days after tumor cell inoculation to enhance vascular endothelial growth factor (VEGF) production [4] . The cyclophosphamide treatments are necessary for consistency in the hematogenous metastasis model. Rats were anesthetized with isoflurane, and a catheter filled with heparinized saline was tied into the right external carotid artery. 231BR-HER2 cells (10 6 ) were infused into the right internal carotid artery.
Hematogenous tumor cell localization
For the MRI brain localization study, FE-Pro labeled 231BR-HER2 breast cancer cells were pretreated with either intetumumab or normal human IgG (0.5 mg/ml; n = 4 per group) in vitro for 5 min prior to intra-carotid infusion. Iron labeled cells were detected as signal dropout on T2*-weighted MR images acquired 1 day after cell infusion.
Hematogenous metastasis imaging and therapy study
Rats were randomly assigned into four groups: (1) control treated weekly with normal human IgG (10 mg/kg IV) (n = 11); (2) INT_in-vitro: intetumumab (0.5 mg/ml) mixed with cells in vitro 5 min before infusion and no further treatment (n = 8); (3) INT_-4h?IV: intetumumab (10 mg/kg IV) 4 h before and weekly after cell infusion (n = 11); (4) INT_IV: intetumumab (10 mg/kg IV) weekly starting 7 days after cell infusion (n = 8). The presence of brain metastases was monitored by MRI at 49-56 days after cell infusion and 77 days if rats were still alive. Rats were euthanized at 20 % weight loss or poor clinical condition, or at the pre-determined study end point of 77 days after tumor cell infusion.
Effect of intetumumab on intracerebral xenograft growth
For intracerebral tumor implantation, female nude rats were anesthetized with ketamine (60 mg/kg IP) and diazepam (7.5 mg/kg IP) and 10 6 231BR-HER2 cells were stereotactically injected in the right caudate putamen (vertical, bregma 6 mm; lateral, bregma 3 mm). To evaluate the effect of in vitro intetumumab treatment, 231BR-HER2 cells were pretreated with intetumumab (0.5 mg/ml) or saline for 5 min before implantation (n = 3 per group) and rats received no further treatment. Rat brains were harvested for tumor volume analysis at 21 days after implantation. To further assess if intetumumab had tumoricidal effects, other rats with intracerebral xenografts of untreated 231BR-HER2 cells were randomized on day three after tumor implantation to receive either no treatment (n = 13) or a single dose of intetumumab (30 mg/kg IV, n = 12) and were followed for survival.
Magnetic resonance imaging (MRI), histology and immunohistochemistry
Standard protocols for MRI, histology and immunohistochemistry have been published previously [24] . T2* MRI signal intensity in regions of interest (ROI) in the right hemisphere versus matched ROI was measured using NIH ImageJ in n = 3 each for control and intetumumab-treated rats. For immunohistochemistry analysis, brains were formalin fixed, sectioned at 100 lm, and every sixth section stained for human mitochondrial antigen. Possible metastases in other tissues were not evaluated. Tumors were manually outlined, including interior holes in large tumors in three control rats and five intetumumab-treated rats. The volume of individual metastases and total tumor burden was assessed using NIH ImageJ software.
Statistical analysis
Summary statistics are presented as medians, and means for numbers and volumes of metastases. The number of metastases at the first MRI or histology, and for volume of metastases by histology was compared using the KruskalWallis test. Survival time was estimated using KaplanMeier estimates from first day of treatment until death or euthanasia. In the latter case, the survival time was censored. The four groups were compared using the log-rank test and, if there were an overall difference between the groups, pair-wise comparisons were made among all pairs using the log-rank test with adjustment based on Tukey's studentized range test. MRI signal intensity measurements were compared using one-way analysis of variance with Tukey's test. Metastasis volume and location in all three intetumumab treatment groups were combined and compared with control metastases using one-way analysis of variance with Dunnett's test. The in vitro adhesion assay and intracerebral xenograft studies were compared by Students t test. Significance was determined at the 5 % level, two-sided, using Microsoft Excel or SAS Ò version 9.
(SAS Institute, 2002-2008).
Results
Human 231BR-HER2 cells expressed a V , a 5 and b 3 integrin but no b 5 integrin by immunoblotting and ELISA and showed abundant a V b 3 but lower a V b 5 integrin (Fig. 1a) . In an in vitro adhesion assay, 89.0 ± 2.9 % of untreated 231BR-HER2 cells adhered to culture plates at 1 h. Incubation with intetumumab (0.5 mg/mL) significantly (p \ 0.05) decreased adhesion to 24.8 ± 17.8 % at 1 h. This inhibitory effect was not found with either trastuzumab or rituximab treatment (Fig. 1b) . Cell viability was 97-100 % regardless of antibody treatment.
In the brain localization study, T2*-weighted MRI signal hypo-intensity (black dots) indicating the presence of iron-labeled cells was observed at 1 day after infusion of both control and intetumumab treated cells (Fig. 1c) . There are significantly (p \ 0.001) more labeled cells in the right hemisphere than left hemisphere in all animals (note MRI shows the right hemisphere on the left side). Quantification of the percentage of brain showing iron signal on MRI showed no difference due to intetumumab pretreatment (Fig. 1c) .
In the hematogenous metastasis study, eight of nine (89 %) evaluable control rats developed multiple ([3) brain metastases and only one of nine rats showed no metastases on the first MRI at 49-56 days after cell infusion ( Fig. 2 and Table 1 ). In contrast, no brain lesions were detected in 13 of 24 rats in all intetumumab groups, and only four rats (17 %) showed multiple metastases. Individually, each intetumumab group differed from control as follows: INT_in-vitro, p = 0.0071; INT_-4h?IV, p = 0.0071; INT_IV, p = 0.01 (Table 1 ). There were no differences among the three intetumumab treatment groups. Three control rats survived to 77 days and all showed multiple ([3) brain lesions on the second MRI. Six rats in all intetumumab treatment groups combined that were negative for brain lesions on the first MRI showed metastases on the second MRI, but seven surviving rats 2 Two of 11 rats in the control group and one of 11 rats of INT_-4h?IV group died before the first scheduled MRI 3 Two rats in the INT_in-vitro group did not receive MRI due to the MR schedule 4 Two of 11 rats in both the control and INT_-4h?IV groups did not have brain histology due to post mortem degradation 5 For clinical relevance, we categorized the number of brain metastases into three groups: no tumor, 1-3 tumors, suitable for surgical removal, and [3 tumors, which would require whole brain radiation showed no brain metastases on the second MRI. Regardless of treatment paradigm, intetumumab reduced the incidence of multiple brain metastases on MRI.
In histological analysis, all evaluable control rats developed multiple brain metastases, although the number and size were variable (median 14, mean 15 ± 9) (Fig. 3a,  b) . Intetumumab-treated rats developed significantly fewer metastases (median 2, mean 4 ± 5, p = 0.0055), with 32 % of animals showing no detectable brain tumors (Table 1) . Normal human IgG used to treat control rats showed no effects on altering body weight and onset of brain metastases. The number of metastases in each intetumumab group significantly (p \ 0.01) differed from control with no difference found among the three intetumumab groups (Fig. 3b) . In those rats with brain metastases, there was no significant difference in total brain tumor volume when comparing control and intetumumab treated rats (Fig. 3c) . Individually, there was a total of 136 brain metastases in nine evaluable control rats with a mean volume of 11.8 ± 20.0 mm 3 , while 101 metastases in 25 intetumumab rats had a mean volume of 26.0 ± 50.9 mm 3 ( Fig. 3d) .
Control
INT_in-vitro In the 231BR-HER2 hematogenous metastasis model, intetumumab treatment significantly (p = 0.0277) improved median survival time (52 days in control compared to 77 days in all intetumumab rats combined) (Fig. 4a) . All surviving animals were sacrificed on the predetermined end of study (day 77), so survival time is underestimated. No difference was found among the three intetumumab groups. Individually, only the INT_in-vitro group was statistically different from the control (p = 0.0186). Survival times were negatively correlated with the number of brain metastases on the first MRI (R 2 = 0.54) and histology (R 2 = 0.39) with slope significantly (p \ 0.0001) different from zero, but survival was not correlated with total tumor burden (R 2 = 0.02). All rats with histologically confirmed brain metastases had tumors within anterior brain sections (olfactory bulb through hippocampus) but only half of rats had metastases localized in the cerebellum. Twelve rats, including three of nine control rats and 9 of 17 intetumumab-treated rats, had no tumor in cerebellum and survival was 74.2 ± 5.6 days. In contrast, in 14 rats (6 of 9 control and 8 of 17 intetumumab-treated) with tumor in cerebellum, survival was 63.7 ± 12.9 days (p = 0.0157; Fig. 4b ). There was no obvious toxicity observed in rats given multiple doses of intetumumab (10 mg/kg IV). Control animals showed significant weight loss (-13.1 ± 2.3 %, n = 11). Intetumumab significantly (p \ 0.001) prevented body weight loss independent of treatment paradigm (Fig. 4c) .
INT IV INT_-4h+IV
Two additional studies using an intracerebral xenograft model showed lack of direct anti-tumor effects of intetumumab. If 231BR-HER2 cells were pretreated with saline prior to implantation, tumor volume at 21 days was 59 ± 14, versus 87 ± 33 mm 3 tumor volume when cells were pretreated with intetumumab (p = 0.24; data not shown). In other rats with untreated intracerebral xenografts, survival was 24.0 ± 5.7 days (n = 13) and histological tumor volume of 75 ± 18 mm 3 (n = 5). Rats given a single dose of IV intetumumab 3 days after tumor implantation had a 20.3 ± 3.2 days survival (n = 12), with histological tumor volume of 90 ± 19 mm 3 (n = 10; data not shown).
Discussion
Intetumumab and other integrin-targeting agents
In this study we demonstrate that intetumumab anti-a V integrin mAb delayed the onset and decreased the total incidence of brain metastases, and significantly improved overall survival in a hematogenous brain metastasis model. A similar result was reported in nude rats by Ning et al. [26] , who found that weekly IP administration of intetumumab reduced pulmonary metastases after IV injection of lung carcinoma cells, with over half of the animals showing no pulmonary metastases. Intetumumab also decreased spontaneous metastasis of breast cancer to the lung in both orthotropic and tail vein injection models in mice [25] . Unfortunately, brain metastases were not assessed in either study.
Other integrin-targeting agents have also shown antitumor and anti-metastatic characteristics [13, 15, 27] . Cilengitide, a cyclic peptide targeted to a V b 3 and a V b 5 integrins, inhibited breast cancer bone metastasis in mice [13] . The mAb etaracizumab, which specifically targets a V b 3 integrin, inhibits melanoma xenograft growth in mice, although metastasis was not evaluated [15] . Knockdown integrin a V was found to lose metastatic phenotype in human prostate cancer cells [28, 29] . Antisense a V suppresses tumor growth more strongly than antisense b 3 treatment [30] , suggesting that targeting a pan-a V by intetumumab would be more effective.
Intetumumab mechanisms
The a V integrins are expressed on the surface of most epithelial tumors and expression is altered in tumor progression and metastasis [8, 31] . Integrin signalling through growth factors and cytokines induces tumor cell growth and motility and blocks apoptosis [7, 32] . The absence of a V b 1 and a V b 3 mediated attachment to the ECM can trigger apoptosis [33] . Low dose intetumumab decreased breast tumor cell viability in vitro by blocking binding to vitronectin [25] . However, we found that intetumumab had no direct cytotoxic effect of breast cancer cells both in vitro and in vivo with treating 231BR-HER2 cells with intetumumab in vitro prior to direct intracerebral implantation. This effect was supported by the equivalent efficacy of delayed intetumumab treatment INT_IV and INT_-4h?IV and INT_IV groups in the hematogenous model.
Chen et al. [25] showed that intetumumab prevents integrin binding to ECM molecules, which prevents downstream molecular interactions for cancer cell migration, invasion, and successful metastasis [12, 32] . Several possible integrin dimers might be targeted by intetumumab including integrin a V b 6 , a key regulator in cancer cell invasion and migration [34] , and integrins a V b 1 and a V b 3 , which regulate cellular protrusion and mobility [35] . In addition, our results with nanoparticle labeling shows that blocking a V integrins with intetumumab prior to cell infusion did not decrease tumor cell brain localization despite the transient inhibition of cell adhesion in vitro.
The determination of a dormant or proliferative state in cancer cells is regulated by integrin signaling through the ECM [36] . Intetumumab-treated metastatic cancer cells might fail to adhere to ECM properly and enter dormancy, and will remain dormant until integrin dependant signaling shifted the cells into a proliferative state. Expression of a V integrins is also elevated in endothelial cells during angiogenesis [37, 38] , and is implicated in signal transduction by VEGF in tumor angiogenesis [39] . In contrast to a previous anti-angiogenetic report [18] , we saw no obvious decrease of angiogenesis by intetumumab, as assessed the blood vessel markers VEGFR1/CD31 staining (not shown). However, blood vessel number and size is very heterogeneous among 231BR-HER2 breast cancer brain metastases [40] . We found that intetumumab increased tumor blood volume on dynamic MRI and blood vessel size not number on histology in a lung cancer brain metastasis model [24] . Based upon our results, we conclude that intetumumab reduced brain metastases in this hematogenous model mainly at the cell invasion/migration across brain vasculature and/or dormancy but not through direct cytotoxic effect to the cancer cells.
Limitations of study and clinical significance of intetumumab
The major limitations of this study are: (1) a single cell line was used, additional studies will test other brain seeking cancer cell lines (breast, lung and melanoma); (2) technical limitations of the in vivo cell trafficking with in vitro iron oxide labeling cancer cells by MRI detection and quantification; (3) The treatment regimen for maximal efficacy (dosage, timing and frequency of antibody administration) need be further defined; and (4) detailed molecular mechanism(s) of brain metastasis regulated by intetumumab remained unclear and need to be delineated.
Intetumumab has undergone phase I and II clinical trials in treatment of different tumors and appears to be safe without major cytotoxicity [17, [19] [20] [21] . These studies demonstrated partial responses and improved overall survival in patients treated with intetumumab in combination with chemotherapy, demonstrating a therapeutic effect of blocking a V integrins in systemic cancers [17, [19] [20] [21] . Unfortunately, metastasis incidence was not reported in these clinical studies. Phase III therapeutic trials of intetumumab are planned, which will give us the opportunity to assess the impact on brain metastases.
Our results emphasize the potential prophylactic effect of intetumumab to prevent breast cancer metastases. We suggest that treatment with intetumumab may be especially important to prevent metastasis when tumor cells are released into the vasculature in breast cancer patients who undergo mastectomy. In conclusion, our studies illustrate a promising approach for the prevention of metastatic breast disease by intetumumab. These anti-metastatic effects could ultimately be extended to preventing metastasis in patients with other a V integrin-overexpressing malignancies, including lung carcinoma and melanoma.
